SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 625.53 |
| Enterprise Value ($M) | 591.44 |
| Book Value ($M) | 99.64 |
| Book Value / Share | 1.03 |
| Price / Book | 6.28 |
| NCAV ($M) | 98.17 |
| NCAV / Share | 1.02 |
| Price / NCAV | 6.37 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.48 |
| Return on Assets (ROA) | -0.61 |
| Return on Equity (ROE) | -0.66 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.41 |
| Current Ratio | 10.41 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 109.43 |
| Assets | 110.90 |
| Liabilities | 11.26 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -51.52 |
| Net Income | -47.91 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -38.26 |
| Cash from Investing | -21.53 |
| Cash from Financing | 61.48 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | New Enterprise Associates 16, L.P. | 15.00 | 0.00 | |
| 13G/A | Venrock Healthcare Capital Partners II, L.P. | 1.40 | -83.50 | |
| 13G/A | Frazier Life Sciences Public Fund, L.P. | 11.90 | 44.49 | |
| 13G/A | Rubric Capital Management LP | 4.71 | -16.35 | |
| 13G/A | Rosalind Advisors, Inc. | 1.20 | 41.67 | |
| 13G/A | MAI Capital Management | 2.20 | -1.42 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 521,485 | 1,399,347 | 37.27 | |
| 440,784 | 1,048,151 | 42.05 | |
| 292,152 | 760,229 | 38.43 | |
| 327,555 | 1,049,552 | 31.21 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| TLPH – Talphera, Inc. | TNGX – Tango Therapeutics, Inc. |
| TRDA – Entrada Therapeutics, Inc. | TVTX – Travere Therapeutics, Inc. |
| URGN – UroGen Pharma Ltd. |
Financial data and stock pages provided by
Fintel.io